Verrica Pharmaceuticals Reports Q4 and FY 2025 Financial Results: Key Highlights for Investors

Summary

• Record Revenue Growth: Total revenue grew by 369% to \$35.6 million in 2025, driven by YCANTH^® performance and milestone payments.
• Cost Controls and Profitability Improvements: Selling, general and administrative (SG&A) expenses were reduced by over 40% year-over-year, supporting a drastic reduction in net loss.
• Strong YCANTH^® Commercial Uptake: Net product revenue from YCANTH^® grew 130% to \$15.3 million, with applicator units dispensed nearly doubling to 51,296.
• Strategic Milestones: Global expansion with regulatory milestones in Japan and the EU, and new clinical progress in common warts and basal cell carcinoma (BCC).
• Solid Financial Position: No outstanding debt; cash runway extended into Q1 2027 following a \$50 million capital raise and full debt repayment.

Detailed Financial and Operational Performance

Revenue and Profitability

• Full-Year 2025 Revenue: Total revenue surged to \$35.6 million, up from \$7.6 million in 2024, with net product revenue from YCANTH^® reaching \$15.3 million (up from \$6.6 million), and license/collaboration revenue at \$20.3 million (up from \$1.0 million) due to milestone payments and the Torii partnership.
• Q4 2025 Revenue: Net product revenue for Q4 was \$3.7 million (Q4 2024: \$0.3 million), license/collaboration revenue at \$1.4 million (Q4 2024: not material).
• Expenses: SG&A expenses for 2025 were \$35.2 million, down from \$58.8 million in 2024. R&D expenses fell to \$8.9 million from \$11.8 million, reflecting lower clinical costs for VP-315.
• Net Losses Sharply Reduced: FY 2025 net loss was \$17.9 million (\$1.68/share) vs. \$76.6 million (\$14.78/share) in 2024. Non-GAAP net loss improved to \$13.2 million (\$1.24/share) from \$64.6 million (\$12.47/share).
• Balance Sheet Strength: Cash and equivalents at \$30.1 million (down from \$46.3 million at 2024 year-end); no outstanding debt after using proceeds from a \$50 million private placement to repay all borrowings.

Commercial Highlights and Pipeline Progress

• YCANTH^® Commercial Performance: Dispensed applicator units grew 99% to 51,296 in 2025, with Q4 units up 58% YoY. February 2026 saw record sales per selling day.
• Global Expansion:
  • Japan: Torii Pharmaceutical, in partnership with Verrica, launched YCANTH^® for molluscum contagiosum in February 2026 after Japanese regulatory approval in September 2025.
  • Europe: Gained alignment with the European Medicines Agency (EMA) to file for approval in the EU without additional clinical studies, significantly de-risking and accelerating the European commercial pathway.
• Clinical Pipeline:
  • Common Warts: First patient dosed in a Phase 3 study in December 2025; a second Phase 3 trial is planned for the US and Japan in partnership with Torii in mid-2026. YCANTH^® could become the first approved common warts therapy in the US or Japan (potential market: 22 million US patients alone).
  • VP-315 (Ruxotemitide) for BCC: Advancing toward Phase 3 trials in 2026. Phase 2 data presented at SITC showed a 97% objective response rate and 86% tumor size reduction; new abscopal effect data indicates immune engagement with a 67% reduction in untreated lesions. FDA aligned with trial design, paving the way for a potential New Drug Application (NDA) with two placebo-controlled Phase 3 studies (n~100 each).
• Product Access Initiatives: Launch of YcanthRx, a non-dispensing pharmacy hub, to streamline prescription fulfillment and access for patients and providers.
• New Leadership: Appointment of Chris Chapman as Chief Commercial Officer, bringing over 25 years of industry experience, including at Dermavant (VTAMA^® launch).

Potentially Price-Sensitive and Shareholder-Relevant Developments

• Debt-Free Status: The company has repaid all outstanding borrowings and exited its prior credit agreement, improving its leverage and financial flexibility.
• Cash Runway Extension: Current cash is expected to fund operations into Q1 2027, reducing near-term dilution risk.
• International Market Entry: Commercial launches and regulatory milestones in Japan and imminent EU filing open significant new revenue streams.
• Regulatory De-Risking: EMA feedback removes the need for further Phase 3 studies for YCANTH^® in Europe, potentially accelerating market access.
• Clinical Readouts: Upcoming pivotal trials for common warts and BCC; positive outcomes could be transformational and drive additional value.
• Operational Efficiencies: SG&A cost reductions and improved commercial execution position Verrica for better profitability as revenues scale.
• Potential for Non-Dilutive Capital: Ongoing discussions for additional international partnerships, which could bring in significant non-dilutive funding and future revenue.

Conference Call Information

Verrica will host a conference call on March 11, 2026, at 8:30 am ET to discuss results and provide a business update.
US Toll-Free: 1-800-343-4136 | International: 1-203-518-9843 | Conference ID: VERRICA
Webcast Link

Conclusion

Verrica Pharmaceuticals delivered a record year in 2025, achieving robust revenue growth, dramatic cost reductions, debt elimination, and extending its cash runway. The Company is positioned for further growth in 2026 with new international markets, pivotal clinical trial catalysts, and an expanding dermatology pipeline. With regulatory de-risking in the EU, the first-ever commercial launch of YCANTH^® for molluscum in Japan, and a new market opportunity in common warts, Verrica’s operational momentum and strategic execution could materially impact future share value.

Investors should closely monitor: upcoming clinical trial results, regulatory filings in Europe, further commercial expansion partnerships, and the company’s ability to sustain sales growth and operational efficiency gains.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with their financial advisors before making investment decisions. Forward-looking statements are subject to risks and uncertainties as described in Verrica’s SEC filings. The author assumes no liability for investment actions taken based on this article.

View Verrica Pharmaceuticals Inc. Historical chart here